C CYTOKINETICS INC
$66.73
| Market Cap | $8.22B |
| P/E Ratio | — |
| Forward P/E | -13.52 |
| Dividend Yield | — |
| Beta | 0.48 |
| 52W Range | $29.84 - $70.10 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $608.00K | 9,584 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 58 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Robert I BlumPresident & CEO | Sale | 7,500 | $66.63 | $499.72K | 01 Apr 2026 | 01 Apr 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 3,639 | $65.00 | $236.53K | 31 Mar 2026 | 31 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 1,930 | $62.07 | $119.80K | 18 Mar 2026 | 18 Mar 2026 |
| Malik Fady IbrahamEVP Research & Development | Sale | 4,397 | $62.15 | $273.27K | 17 Mar 2026 | 17 Mar 2026 |
| Malik Fady IbrahamEVP Research & Development | Sale | 7,636 | $62.15 | $474.58K | 17 Mar 2026 | 17 Mar 2026 |
| Blum Robert IPresident & CEO | Sale | 23,928 | $62.15 | $1.49M | 17 Mar 2026 | 17 Mar 2026 |
| Blum Robert IPresident & CEO | Sale | 12,673 | $62.15 | $787.63K | 17 Mar 2026 | 17 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 2,916 | $62.15 | $181.23K | 17 Mar 2026 | 17 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 5,626 | $62.15 | $349.66K | 17 Mar 2026 | 17 Mar 2026 |
| Lee SungEVP, Chief Financial Officer | Sale | 4,935 | $62.15 | $306.71K | 17 Mar 2026 | 17 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 1,709 | $61.03 | $104.30K | 16 Mar 2026 | 16 Mar 2026 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,907 | $60.72 | $176.51K | 09 Mar 2026 | 09 Mar 2026 |
| Blum Robert IPresident & CEO | Sale | 7,931 | $60.72 | $481.57K | 09 Mar 2026 | 09 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 2,582 | $60.72 | $156.78K | 09 Mar 2026 | 09 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 15,000 | $61.87 | $928.05K | 05 Mar 2026 | 05 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 11,000 | $61.88 | $680.68K | 05 Mar 2026 | 05 Mar 2026 |
| PARSHALL B LYNNE | Sale | 5,000 | $61.21 | $306.05K | 02 Mar 2026 | 02 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 886 | $61.62 | $54.60K | 02 Mar 2026 | 02 Mar 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 15,000 | $61.93 | $928.95K | 05 Feb 2026 | 05 Feb 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 15,000 | $61.93 | $928.95K | 05 Feb 2026 | 05 Feb 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 886 | $62.10 | $55.02K | 02 Feb 2026 | 02 Feb 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 886 | $62.10 | $55.02K | 02 Feb 2026 | 02 Feb 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 15,000 | $60.28 | $904.20K | 05 Jan 2026 | 05 Jan 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 15,000 | $60.28 | $904.20K | 05 Jan 2026 | 05 Jan 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 885 | $63.16 | $55.90K | 02 Jan 2026 | 02 Jan 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 913 | $62.09 | $56.69K | 02 Jan 2026 | 02 Jan 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 913 | $62.09 | $56.69K | 02 Jan 2026 | 02 Jan 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 885 | $63.16 | $55.90K | 02 Jan 2026 | 02 Jan 2026 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 1,809 | $62.44 | $112.95K | 29 Dec 2025 | 30 Dec 2025 |
| Andrew CallosEVP, Chief Commercial Officer | Sale | 1,809 | $62.44 | $112.95K | 29 Dec 2025 | 30 Dec 2025 |
| WIERENGA WENDELL | Sale | 20,000 | $66.14 | $1.32M | 22 Dec 2025 | 23 Dec 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,200 | $61.24 | $134.73K | 16 Dec 2025 | 16 Dec 2025 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 1,042 | $65.96 | $68.73K | 08 Dec 2025 | 08 Dec 2025 |
| Callos AndrewEVP, Chief Commercial Officer | Sale | 52,486 | $65.95 | $3.46M | 05 Dec 2025 | 05 Dec 2025 |
| HENDERSON JOHN T | Sale | 8,750 | $63.90 | $559.13K | 02 Dec 2025 | 02 Dec 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,200 | $63.89 | $140.56K | 02 Dec 2025 | 02 Dec 2025 |
| Fady Ibraham MalikEVP Research & Development | Sale | 2,200 | $63.89 | $140.56K | 02 Dec 2025 | 02 Dec 2025 |
| John T HendersonDirector | Sale | 8,750 | $63.90 | $559.13K | 02 Dec 2025 | 02 Dec 2025 |
| Harrington Robert Arthur | Sale | 2,150 | $66.80 | $143.62K | 01 Dec 2025 | 02 Dec 2025 |
| Kaye Edward M. MD | Sale | 28,064 | $66.72 | $1.87M | 01 Dec 2025 | 02 Dec 2025 |
| Edward M. Kaye MDDirector | Sale | 28,064 | $66.72 | $1.87M | 01 Dec 2025 | 02 Dec 2025 |
| Robert Arthur HarringtonDirector | Sale | 2,150 | $66.80 | $143.62K | 01 Dec 2025 | 02 Dec 2025 |
| PARSHALL B LYNNE | Sale | 5,000 | $64.73 | $323.65K | 19 Nov 2025 | 19 Nov 2025 |
| Lynne B ParshallDirector | Sale | 5,000 | $64.73 | $323.65K | 19 Nov 2025 | 19 Nov 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,200 | $66.45 | $146.19K | 18 Nov 2025 | 18 Nov 2025 |
| Kaye Edward M. MD | Sale | 5,175 | $65.08 | $336.79K | 11 Nov 2025 | 12 Nov 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,295 | $59.55 | $136.67K | 04 Nov 2025 | 04 Nov 2025 |
| Fady Ibraham MalikEVP Research & Development | Sale | 2,295 | $59.55 | $136.67K | 04 Nov 2025 | 04 Nov 2025 |
| Blum Robert IPresident & CEO | Sale | 5,000 | $62.86 | $314.30K | 30 Oct 2025 | 30 Oct 2025 |
| Robert I BlumPresident & CEO | Sale | 5,000 | $62.86 | $314.30K | 30 Oct 2025 | 30 Oct 2025 |
| WIERENGA WENDELL | Sale | 4,375 | $58.68 | $256.73K | 27 Oct 2025 | 27 Oct 2025 |
| Wendell WierengaDirector | Sale | 4,375 | $58.68 | $256.73K | 27 Oct 2025 | 27 Oct 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,105 | $58.22 | $122.55K | 21 Oct 2025 | 21 Oct 2025 |
| Fady Ibraham MalikEVP Research & Development | Sale | 2,105 | $58.22 | $122.55K | 21 Oct 2025 | 21 Oct 2025 |
| Blum Robert IPresident & CEO | Sale | 5,000 | $60.03 | $300.15K | 16 Oct 2025 | 16 Oct 2025 |
| Robert I BlumPresident & CEO | Sale | 5,000 | $60.03 | $300.15K | 16 Oct 2025 | 16 Oct 2025 |
| Malik Fady IbrahamEVP Research & Development | Sale | 2,000 | $60.56 | $121.12K | 07 Oct 2025 | 07 Oct 2025 |
| Kaye Edward M. MD | Sale | 6,757 | $60.00 | $405.42K | 06 Oct 2025 | 06 Oct 2025 |
Frequently Asked Questions
What is CYTK stock price today?
CYTOKINETICS INC (CYTK) is currently trading at $66.73. The stock has a 52-week range of $29.84 to $70.10 and a market capitalization of $8.22B.
Is CYTK a good stock to buy in 2026?
CYTOKINETICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +64.7%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling CYTK stock?
There have been 58 insider transactions for CYTK in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has CYTK stock performed over the past year?
CYTOKINETICS INC (CYTK) has returned +64.7% over the past 12 months. The stock traded between $29.84 and $70.10 during this period, and is currently at $66.73.
Which hedge funds own CYTK (CYTOKINETICS INC)?
1 tracked hedge funds currently hold CYTK in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is CYTK's market cap and valuation?
CYTOKINETICS INC (CYTK) has a market capitalization of $8.22B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is CYTK's revenue and profitability?
CYTOKINETICS INC reported revenue of $88.04M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.48.
What sector is CYTK in and who are its biggest institutional holders?
CYTOKINETICS INC (CYTK) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.